Debt FinancingFormycon successfully placed a €70M senior unsecured and floating rate bond, which will be used to finance the development and expansion of the company’s biosimilar product portfolio.
PartnershipsFormycon entered into a distribution agreement with ratiopharm GmbH for the semi-exclusive commercialization of Stelera biosimilar FYB202/Fymskina in Germany.
Regulatory And Market AccessFYB202 was assigned a permanent, product-specific reimbursement code (Q-code) in the U.S., facilitating reimbursement by payors.